Dr. Peter Høngaard Andersen holds a B.Sc. in Chemistry, an M.Sc. in Biochemistry, is an M.D. and has many years’ experience and a broad network from his previous positions within the Life Science and biotech industries. Dr. Høngaard Andersen also has many years of experience in pharmaceutical research and development from the pharmaceutical industry: 14 years at Novo Nordisk in CNS, neuroendocrinology, women’s health and type-2 diabetes and 15 years at Lundbeck in CNS pharmaceutical research and early development. Dr. Høngaard Andersen has been involved in the research and development of several pharmaceuticals on the market (e.g. Norditropine, Simplex, Victoza, Trintellix / Brintellix, Cipralex).
Dr. Høngaard Andersen has been a founder or co-founder of several biotech companies, including Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics and Prexton Pharmaceuticals. Dr. Høngaard Andersen was involved in the Innovative Medicines Initiative (IMI) from its inception in 2003 and served as Chairman of the industry side of IMI from 2009–2014. In addition, Dr Høngaard Andersen is a Venture Partner in Ysios Capital and a member of the Advisory Board in Eir Ventures.
Current assignments: Chairman of Scandion Oncology A/S and the Innovation Board of the Danish Regional Council. In addition, Dr Høngaard is a Venture Partner in Ysios Capital and a member of the Advisory Board in Eir Ventures.
Previous assignments (last five years): Founder and former CEO of Innovation Fund Denmark, member of the Executive Committee of IC Permed (the International Consortium of Personalized Medicine) and Chairman of Prexton Therapeutics.